The development of an effective vaccine has been hindered by the enormous diversity of
human immunodeficiency virus‐1 (HIV‐1) and its ability to escape a myriad of host immune …

Antibodies that neutralize diverse strains of HIV-1 develop in∼ 20% of HIV-1-infected
individuals, and isolation and structural characterization of these antibodies are revealing …

Vaccines are urgently needed to control the ongoing pandemic COVID-19 and previously
emerging MERS/SARS caused by coronavirus (CoV) infections. The CoV spike receptor …

Abstract The Antibody Mediated Prevention trials showed that the broadly neutralizing
antibody (bnAb) VRC01 prevented acquisition of human immunodeficiency virus-1 (HIV-1) …

HIV-1 therapy with single or dual broadly neutralizing antibodies (bNAbs) has shown viral
escape, indicating that at least a triple bNAb therapy may be needed for robust suppression …

HIV cure has been reported for five individuals who underwent allogeneic hematopoietic
stem cell transplantation (allo-HSCT) with cells from CCR5Δ32 homozygous donors. By …

Monoclonal antibody 10-1074 targets the V3 glycan supersite on the HIV-1 envelope (Env)
protein. It is among the most potent anti-HIV-1 neutralizing antibodies isolated so far. Here …

HIV-1 immunotherapy with a combination of first generation monoclonal antibodies was
largely ineffective in pre-clinical and clinical settings and was therefore abandoned …

Interruption of combination antiretroviral therapy (ART) in HIV-1-infected individuals leads to
rapid viral rebound. Here we report the results of a phase IIa open label clinical trial …

Eliciting potent and broadly neutralizing antibodies (bnAbs) is a major goal in HIV-1 vaccine
development. Here, we describe how germline-targeting immunogen BG505 SOSIP …